Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BNTC Benitec Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: BNTC
Price (delayed)
$13.6
Market cap
$348.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
$0
Enterprise value
$245.42M
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It
Highlights
The company's EPS has surged by 100% YoY
The equity has grown by 28% from the previous quarter
The debt has soared by 171% YoY
The company's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of BNTC
Market
Valuations
Earnings
Shares outstanding
25.6M
Market cap
$348.16M
Enterprise value
$245.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.27
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$30.14M
Net income
-$26.49M
EBIT
-$25.16M
EBITDA
-$24.79M
Free cash flow
-$18.69M
Per share
Balance sheet
Liquidity
EPS
$0
EPS diluted
$0
Free cash flow per share
-$0.48
Book value per share
$4.16
Revenue per share
$0
TBVPS
$2.73
Total assets
$105.21M
Total liabilities
$7.64M
Debt
$959,000
Equity
$97.57M
Working capital
$96.98M
Debt to equity
0.01
Current ratio
14.8
Quick ratio
14.76
Net debt/EBITDA
4.14
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-35.5%
Return on equity
-38.1%
Return on invested capital
N/A
Return on capital employed
-25.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BNTC stock price
How has the Benitec Biopharma stock price performed over time
Intraday
0.74%
1 week
-0.22%
1 month
-0.33%
1 year
43.61%
YTD
7.68%
QTD
4.53%
Financial performance
How have Benitec Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.14M
Net income
-$26.49M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
The operating income has declined by 40% year-on-year and by 25% since the previous quarter
BNTC's net income is down by 24% since the previous quarter and by 22% year-on-year
Price vs fundamentals
How does BNTC's price correlate with its fundamentals
Growth
What is Benitec Biopharma's growth rate over time
Valuation
What is Benitec Biopharma stock price valuation
P/E
N/A
P/B
3.27
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 100% YoY
BNTC's P/B is 31% above its last 4 quarters average of 2.5 and 2.2% above its 5-year quarterly average of 3.2
The equity has grown by 28% from the previous quarter
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Benitec Biopharma business performance
Benitec Biopharma's return on equity has surged by 79% YoY and by 14% QoQ
Benitec Biopharma's ROA has soared by 73% YoY and by 13% from the previous quarter
Dividends
What is BNTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BNTC.
Financial health
How did Benitec Biopharma financials performed over time
Benitec Biopharma's total liabilities has soared by 144% from the previous quarter and by 118% YoY
The company's quick ratio fell by 42% QoQ
The debt is 99% less than the equity
The debt has soared by 171% YoY
The debt to equity has plunged by 67% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.